SENECA VALLEY VIRUS (SVV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Not applicable: Agent is ubiquitous on all or most US farms; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Seneca Valley virus (SVV) is a picornavirus in the genus Senecavirus that causes vesicular disease in pigs clinically indistinguishable from foot-and-mouth disease (FMD), swine vesicular disease (SVD), and vesicular stomatitis (VS). First isolated from pig samples in the United States between 1988 and 2001, SVV was initially considered an incidental finding. Since 2014-2015, however, SVV has emerged as a significant cause of vesicular disease outbreaks in North America, South America, and Asia. The virus has been detected in at least 10 US states, Canada, Brazil, China, Thailand, Colombia, Vietnam, India, Chile, and England (first detection 2022). All known SVV isolates belong to a single serotype. Clinical disease includes vesicular lesions on the snout and feet (coronary bands, dewclaws, interdigital space) that are indistinguishable from FMD, making laboratory differentiation mandatory. A distinctive feature of SVV outbreaks is epidemic transient neonatal losses (ETNL)—acute mortality in 1-week-old piglets reaching 20-70% on affected farms, occurring without the vesicular lesions seen in adult pigs. Neonatal piglets show diarrhea, muscle weakness, neurological signs, and sudden death. The pathogenesis of ETNL remains poorly understood. SVV has been detected in mice and house flies on affected farms, suggesting potential environmental reservoirs or vectors. Interestingly, one SVV isolate (SVV-001) has been developed as an oncolytic cancer therapy in humans due to its ability to selectively kill tumor cells while sparing normal cells.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter states: "SVV has no known public health significance." No human infections have been documented despite widespread pig exposure to the virus since at least 1988. The development of SVV-001 as a human cancer therapy demonstrates the virus's lack of pathogenicity in normal human tissues—it kills cancer cells but not normal cells. There is no evidence of foodborne transmission risk.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
SVV does not infect humans through any route. Laboratory workers and farm personnel have been exposed without documented infections. The virus's development as a cancer therapy involved extensive human safety testing, confirming its non-pathogenicity for humans.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Not applicable: Agent is ubiquitous on all or most US farms
SVV transmission routes are not fully established but likely include fecal-oral and direct contact through skin abrasions. Several factors suggest moderate biosecurity bypass: (1) Environmental contamination: SVV has been isolated from mice and house flies on affected farms, with identical viral sequences in pigs, mice, and flies; (2) Feed transmission: SVV RNA was detected in feed and ingredients on Brazilian farms, and experimental spiking showed infectious virus recoverable for up to 37 days in feed; (3) Vertical transmission: suggested but not proven; (4) Shedding pattern: virus detected 1-28 days post-infection in oral/nasal secretions and feces; viral RNA persists in tonsils for up to 38 days; (5) Apparent rapid spread: outbreaks have affected multiple geographic regions in relatively short timeframes (rapid emergence across Brazil 2014-2015, spread to multiple Asian countries). However, the virus is susceptible to hydrogen peroxide and potassium peroxymonosulfate disinfectants, suggesting standard biosecurity can reduce but not eliminate transmission risk. Stress, particularly during transportation, is "postulated to be a predisposing factor for SVV-associated vesicular disease."
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical diagnosis is complicated by the vesicular lesions being "indistinguishable from those produced by FMDV, SVDV, VSV, and VESV"—laboratory testing is mandatory for any vesicular disease. Additionally, neonatal piglets with ETNL typically do not show vesicular lesions, presenting instead with non-specific signs (diarrhea, weakness, neurological signs, sudden death). Once SVV is suspected, laboratory confirmation is straightforward: virus isolation in multiple cell lines (PK-15, IB-RS-2, ST, Vero, LFBKαVβ6); TaqMan real-time RT-PCR targeting 3D or 5'-UTR regions; conventional RT-PCR targeting VP3/VP1; isothermal amplification methods (RT-LAMP, RPA) for field use; immunohistochemistry and in situ hybridization for tissue detection; and serology via IFA, VP-based ELISA, or virus neutralization. Cross-reactivity exists between historical and contemporary SVV isolates, simplifying serological diagnosis. The critical challenge is recognizing that vesicular disease may be present—any vesicle in a pig must be treated as potential FMD until proven otherwise.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
SVV causes economic losses through two distinct syndromes: (1) Vesicular disease in adults: lameness affecting up to 80-90% of pigs; vesicles and erosions on coronary bands and snouts; lethargy at 4 days post-infection lasting 2-10 days; lesions resolve by 12-16 days. Adult mortality is rare and effects on farrowing in pregnant sows were not observed; (2) Epidemic transient neonatal losses (ETNL): mortality of 20-70% in neonatal piglets (1 week old); clinical signs include diarrhea, muscle weakness, neurological signs, sudden death; piglets that survive usually recover in 3-10 days. The combination of high piglet mortality on affected farms with transient but significant morbidity in growing/finishing pigs creates substantial production losses during outbreaks. However, disease appears to be self-limiting—farms recover and the economic impact is concentrated in the acute outbreak period rather than causing chronic ongoing losses. The sporadic, epidemic nature of outbreaks means some farms are severely affected while most remain unaffected.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
SVV is not a WOAH-listed disease and does not trigger trade restrictions or regulatory notifications. The primary regulatory concern is ruling out FMD when vesicular disease is detected—once FMD, SVDV, and VS are excluded and SVV confirmed, no trade restrictions apply. However, the mandatory laboratory investigation of vesicular disease creates temporary market disruption during the diagnostic process. SVV does not affect export market access or disease-free status claims. Consumer concerns are minimal since the virus has no public health significance.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
SVV is a viral pathogen (positive-sense single-stranded RNA senecavirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. All SVV isolates belong to a single serotype with cross-neutralization between historical (pre-2010) and contemporary (post-2011) isolates, though genetic divergence of ~6% exists between these groups. Some contemporary isolates show differences in virulence, but this represents viral evolution rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for SVV. Disease is self-limiting with most pigs recovering without intervention. Management focuses on biosecurity to prevent introduction and supportive care during outbreaks. Antimicrobials are not routinely used for SVV prevention or treatment. Any antimicrobial use would be for secondary bacterial infections of ruptured vesicles—rare, individual animal treatment.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments exist for SVV infection. Adult pigs typically recover spontaneously within 12-16 days as vesicular lesions heal. For ETNL in neonatal piglets, no treatments can prevent mortality—supportive care is palliative only. No antiviral drugs are available for SVV.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
The chapter states: "No commercial SVV vaccines are currently available." Experimental vaccines have shown promise: inactivated cell culture-derived SVV vaccines have been successfully tested; maternal antibodies from vaccinated sows protected 3-6 day old suckling piglets against SVV challenge; and a live-attenuated recombinant vaccine candidate "induced robust VN antibodies, T-cell proliferation, and protected pigs against heterologous SVV challenge." The single serotype of SVV (with cross-neutralization between historical and contemporary isolates) suggests that an effective vaccine could provide broad protection. However, no commercial product is currently available for use in the field.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
SVV eradication from the US pig population is not feasible because: (1) Widespread distribution: SVV has been detected in at least 10 US states and appears to be endemic in the domestic pig population; (2) Environmental persistence: SVV detected in mice and house flies on affected farms suggests environmental reservoirs; infectious virus recoverable from contaminated feed for up to 37 days; (3) Potential secondary hosts: mice experimentally susceptible to SVV infection, suggesting possible wildlife reservoir; (4) Subclinical infection: many infections may not cause obvious disease, allowing silent circulation; (5) Tonsil persistence: viral RNA detected in tonsils up to 38 days post-infection, creating prolonged shedding opportunity; (6) Global spread: the virus has spread rapidly to multiple continents since 2014, suggesting efficient transmission that would allow reintroduction. The practical approach is managing clinical outbreaks through biosecurity enhancement, stress reduction, and supportive care rather than attempting eradication. Development of commercial vaccines would provide an additional control tool but would not enable eradication given the virus's apparent ability to persist in environmental reservoirs.